Lexaria Bioscience Corp. (NASDAQ:LEXX) shares lost ground Thursday. The global innovator in drug delivery platforms announces positive final results from its recently completed human Pilot Study #1 evaluating DehydraTECHTM technology for the oral delivery of the glucagon-like peptide-1 drug semaglutide available commercially in the branded product Rybelsus®.
The study was performed by a prominent university research center comparing a single 7 mg semaglutide dose of a Rybelsus® tablet to a matching dose from Rybelsus that had been compound formulated in capsule form using DehydraTECH processing technology enhancements.
In general, the DehydraTECH processing enabled improvements in delivery of semaglutide to the bloodstream, and the improvements in controlling blood sugar were more pronounced in the final combined results of the Study than they were in the first half of the Study as reported in press releases issued November 27 and November 28, 2023.
The first post-baseline blood was sampled 20 minutes after oral administration and, at that point in time, the DehydraTECH GLP-1 blood semaglutide level was ~261% higher than that of the Control, demonstrating DehydraTECH’s well-known ability to deliver drugs to the bloodstream faster. At each of the 19 blood sample time points, the DehydraTECH GLP-1 blood semaglutide levels were higher than the Control levels. The peak levels of semaglutide in blood were 43% higher in the DehydraTECH GLP-1 than in the Rybelsus® Control.
LEXX shares dipped six cents, or 4.6%, to $1.24.
Related Stories
